Literature DB >> 23884239

Cross reactivity of serum antibody responses elicited by DNA vaccines expressing HA antigens from H1N1 subtype influenza vaccines in the past 30 years.

Iman Almansour1, Huaiqing Chen1, Shixia Wang1, Shan Lu1.   

Abstract

In the past three decades, ten H1 subtype influenza vaccines have been recommended for global seasonal flu vaccination. Some of them were used only for one year before being replaced by another H1 flu vaccine while others may be used for up to seven years. While the selection of a new seasonal flu vaccine was based on the escape of a new emerging virus that was not effectively protected by the existing flu formulation, there is limited information on the magnitude and breadth of cross reactivity among H1 subtype virus circulation over a long period. In the current study, HA-expressing DNA vaccines were constructed to express individual HA antigens from H1 subtype vaccines used in the past 30 y. Rabbits naïve to HA antibody responses were immunized with these HA DNA vaccines and the cross reactivity of these sera against HA antigen and related H1 viruses in the same period was studied. Our data indicate that the level of cross reactivity was different for different viral isolates and the key mutations responsible for the cross reactivity may involve only a limited number of residues. Our results provide useful information for the development of improved seasonal vaccines than can achieve broad protection against viruses within the same H1 subtype.

Entities:  

Keywords:  DNA vaccine; H1N1; antibody; hemagglutinin; influenza

Mesh:

Substances:

Year:  2013        PMID: 23884239      PMCID: PMC3906389          DOI: 10.4161/hv.25735

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  39 in total

1.  Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP).

Authors:  C B Bridges; K Fukuda; N J Cox; J A Singleton
Journal:  MMWR Recomm Rep       Date:  2001-04-20

2.  Structural basis of preexisting immunity to the 2009 H1N1 pandemic influenza virus.

Authors:  Rui Xu; Damian C Ekiert; Jens C Krause; Rong Hai; James E Crowe; Ian A Wilson
Journal:  Science       Date:  2010-03-25       Impact factor: 47.728

3.  Hemagglutinin (HA) proteins from H1 and H3 serotypes of influenza A viruses require different antigen designs for the induction of optimal protective antibody responses as studied by codon-optimized HA DNA vaccines.

Authors:  Shixia Wang; Jessica Taaffe; Christopher Parker; Alicia Solórzano; Hong Cao; Adolfo García-Sastre; Shan Lu
Journal:  J Virol       Date:  2006-09-20       Impact factor: 5.103

4.  Annual report of the National Influenza Surveillance Scheme, 2007.

Authors:  Rhonda Owen; Ian G Barr; Andrew Pengilley; Conan Liu; Bev Paterson; Marlena Kaczmarek
Journal:  Commun Dis Intell Q Rep       Date:  2008-06

5.  Safety and immunogenicity of low and high doses of trivalent live cold-adapted influenza vaccine administered intranasally as drops or spray to healthy children.

Authors:  J C King; R Lagos; D I Bernstein; P A Piedra; K Kotloff; M Bryant; I Cho; R B Belshe
Journal:  J Infect Dis       Date:  1998-05       Impact factor: 5.226

6.  The antigenic structure of the influenza virus A/PR/8/34 hemagglutinin (H1 subtype).

Authors:  A J Caton; G G Brownlee; J W Yewdell; W Gerhard
Journal:  Cell       Date:  1982-12       Impact factor: 41.582

7.  Immunogenicity of inactivated influenza vaccine in residential homes for elderly people.

Authors:  K G Nicholson; D J Baker; P Chakraverty; A Farquhar; D Hurd; J Kent; P A Litton; S H Smith
Journal:  Age Ageing       Date:  1992-05       Impact factor: 10.668

8.  Heterologous HA DNA vaccine prime--inactivated influenza vaccine boost is more effective than using DNA or inactivated vaccine alone in eliciting antibody responses against H1 or H3 serotype influenza viruses.

Authors:  Shixia Wang; Chris Parker; Jessica Taaffe; Alicia Solórzano; Adolfo García-Sastre; Shan Lu
Journal:  Vaccine       Date:  2008-05-19       Impact factor: 3.641

9.  Return of epidemic A1 (H1N1) influenza virus.

Authors:  V M Zhdanov; D K Lvov; L Y Zakstelskaya; M A Yakhno; V I Isachenko; N A Braude; V I Reznik; T V Pysina; V P Andreyev; R Y Podchernyaeva
Journal:  Lancet       Date:  1978-02-11       Impact factor: 79.321

10.  Course of seasonal influenza A/Brisbane/59/07 H1N1 infection in the ferret.

Authors:  Alexis McBrayer; Jeremy V Camp; Ron Tapp; Vladimir Yamshchikov; Sheila Grimes; Diana L Noah; Colleen B Jonsson; Carl E Bruder
Journal:  Virol J       Date:  2010-07-09       Impact factor: 4.099

View more
  8 in total

1.  Optimal designs of an HA-based DNA vaccine against H7 subtype influenza viruses.

Authors:  Lu Zhang; Na Jia; Jun Li; Yaping Han; Wuchun Cao; Shixia Wang; Zuhu Huang; Shan Lu
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

2.  Identification of Aim2 as a sensor for DNA vaccines.

Authors:  John J Suschak; Shixia Wang; Katherine A Fitzgerald; Shan Lu
Journal:  J Immunol       Date:  2014-12-08       Impact factor: 5.422

3.  Antigen-specific H1N1 influenza antibody responses in acute respiratory tract infections and their relation to influenza infection and disease course.

Authors:  John Patrick Haran; David C Hoaglin; Huaiqing Chen; Edward W Boyer; Shan Lu
Journal:  J Clin Virol       Date:  2014-05-28       Impact factor: 3.168

4.  A cGAS-Independent STING/IRF7 Pathway Mediates the Immunogenicity of DNA Vaccines.

Authors:  John J Suschak; Shixia Wang; Katherine A Fitzgerald; Shan Lu
Journal:  J Immunol       Date:  2015-11-20       Impact factor: 5.422

5.  Construction and Immunogenicity Evaluation of Recombinant Influenza A Viruses Containing Chimeric Hemagglutinin Genes Derived from Genetically Divergent Influenza A H1N1 Subtype Viruses.

Authors:  Kara McCormick; Zhiyong Jiang; Longchao Zhu; Steven R Lawson; Robert Langenhorst; Russell Ransburgh; Colin Brunick; Miranda C Tracy; Heather R Hurtig; Leah M Mabee; Mark Mingo; Yanhua Li; Richard J Webby; Victor C Huber; Ying Fang
Journal:  PLoS One       Date:  2015-06-10       Impact factor: 3.240

6.  A novel DNA and protein combination COVID-19 vaccine formulation provides full protection against SARS-CoV-2 in rhesus macaques.

Authors:  Yuzhong Li; Yanwei Bi; Hongjian Xiao; Yueting Yao; Xiaojuan Liu; Zhengrong Hu; Jinmei Duan; Yaoyun Yang; Zhihua Li; Yadong Li; Heng Zhang; Chen Ding; Jianbo Yang; Haiwei Li; Zhanlong He; Longding Liu; Guangnan Hu; Shuying Liu; Yanchun Che; Shixia Wang; Qihan Li; Shan Lu; Wei Cun
Journal:  Emerg Microbes Infect       Date:  2021-12       Impact factor: 7.163

7.  Self-Assembled Particles Combining SARS-CoV-2 RBD Protein and RBD DNA Vaccine Induce Synergistic Enhancement of the Humoral Response in Mice.

Authors:  Mariya B Borgoyakova; Larisa I Karpenko; Andrey P Rudometov; Ekaterina A Volosnikova; Iuliia A Merkuleva; Ekaterina V Starostina; Alexey M Zadorozhny; Anastasiya A Isaeva; Valentina S Nesmeyanova; Daniil V Shanshin; Konstantin O Baranov; Natalya V Volkova; Boris N Zaitsev; Lyubov A Orlova; Anna V Zaykovskaya; Oleg V Pyankov; Elena D Danilenko; Sergei I Bazhan; Dmitry N Shcherbakov; Alexander V Taranin; Alexander A Ilyichev
Journal:  Int J Mol Sci       Date:  2022-02-16       Impact factor: 5.923

8.  Profiles of acute cytokine and antibody responses in patients infected with avian influenza A H7N9.

Authors:  Rui Huang; Lu Zhang; Qin Gu; Yi-Hua Zhou; Yingying Hao; Kui Zhang; Yong Liu; Danjiang Dong; Shixia Wang; Zuhu Huang; Shan Lu; Chao Wu
Journal:  PLoS One       Date:  2014-07-08       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.